Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Strengthening Position in Projected $51B Global Cannabis Market

Lucy Scientific Discovery (NASDAQ: LSDI) is featured in a recent FinancialNewsMedia (“FNM”) Editorial. The editorial provides an overview of LSDI’s position in a global cannabis market projected to hit $51 billion this year. According to the press release, the global cannabis market has seen consistent growth year after year, with increasing legalization of cannabis fueling that growth. The release notes that a recent Statista report forecast the global cannabis market to reach $51.27 billion in 2023 with revenue expected to show an annual growth rate (“CAGR”) of 14.95%. For the purposes of the report, the cannabis market was categorized into three different “application perspectives”: spiritual purpose, health-condition management and wellness management. “The recreational cannabis market includes the consumption of cannabis for nonmedicinal reasons, such as boosting physical performance, pursuing creative activities, and experiencing spirituality,” the press release stated. “Recreational cannabis can be consumed in the form of extracts, dried cannabis, edibles and beverages. Active cannabis companies in the markets this week include: Lucy Scientific Discovery Inc.”

To view the full press release, visit https://cnw.fm/RRma3

About Lucy Scientific Discovery Inc.

Lucy Scientific Discovery is a NASDAQ company with holdings and operations in a variety of psychotropic businesses. The company holds a Controlled Drugs and Substances Dealer’s license granted by Health Canada’s Office of Controlled Substances. Lucy Scientific Discovery Inc. and its wholly owned subsidiary, LSDI Manufacturing Inc., operate under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada). This specialized license authorizes LSDI to develop, sell, deliver and manufacture pharmaceutical-grade active pharmaceutical ingredients (“APIs”) used in controlled substances and their raw material precursors. With a focus on pioneering innovative therapies for patients in need, Lucy Scientific Discovery is dedicated to advancing the understanding and applications of psychotropic medicines, improving mental health outcomes and enhancing well-being for individuals worldwide. For more information, visit the company’s website at www.LucyScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to LSDI are available in the company’s newsroom at https://cnw.fm/LSDI

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — NY Recreational Cannabis Rollout Hits Another Snag as Judge Halts Business Licensing

The rollout of recreational cannabis in New York has faced yet another hurdle as a judge from the state’s Supreme Court has put a halt on all applications for business licenses to establish adult-use marijuana dispensaries. The judge cited inconsistent and unclear information from regulating officials. This recent setback adds to the challenges that have characterized the launch of legalized marijuana in New York.

The issue revolves around a program called the Conditional Adult Use Retail Dispensary (CAURD), managed by the Office of Cannabis Management (OCM). When the state legalized marijuana in March 2021, lawmakers and cannabis regulators initially announced that a portion of retail licenses would be reserved for small nonprofit organizations and individuals who had been adversely affected by the war on drugs.

This exclusion left out several potential marijuana businesses, including those with existing medical cannabis licenses, often owned by larger multistate operators. Some of these operators took legal action against the state earlier this year. Additionally, a group of service-disabled military veterans filed a lawsuit against the state, arguing that the CAURD program violates their rights and is unconstitutional because they were not eligible for permits.

As a response to this lawsuit, Judge Kevin Bryant, presiding over the State Supreme Court, issued an injunction on Aug. 7, 2023, which temporarily suspended all CAURD applications. This injunction was subsequently upheld on Aug. 18. While the OCM has granted licenses to a few hundred emerging CAURD businesses, records from the agency indicate that only 23 legal marijuana retail stores are operational in the state. Interestingly, more than 1,500 unlicensed cannabis retailers are currently operating exclusively in New York City.

Last week, a glimmer of hope emerged for certain applicants when the state released a list of 30 CAURD applicants that had made significant progress in the application process and were thus exempt from Judge Bryant’s order. However, in a subsequent ruling last week, Bryant noted that information from the OCM indicated that not all 30 applicants had fulfilled the necessary licensing prerequisites. As a result, he directed OCM to provide an updated list of potential injunction-exempt applicants under oath, planning a comprehensive, individualized order.

This series of events has taken many by surprise and left both applicants and observers feeling perplexed. Osbert Orduña, CEO of the Cannabis Place, which is in the process of applying for a CAURD license to operate in Queens, expressed disappointment in the recent developments. He emphasized that this setback has negative repercussions for small businesses, potential employees and cannabis consumers in New York — all affected by a lawsuit initiated by a small group of individuals.

These regulatory hiccups can be massively disruptive, and even established companies such as Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) may possibly reconsider staying in a market that doesn’t have a reliable regulatory regime guiding operators, creating uncertainty about the stability of the rules under which they operate.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Planet 13 to Expand into Florida with Planned Acquisition of VidaCann

Planet 13 Holdings has announced a $48.9 million acquisition of VidaCann, a vertically integrated cannabis operator in Florida with 26 medical marijuana dispensaries. A recent news release revealed that both companies’ boards unanimously approved the total acquisition of VidaCann’s debt, cash and stock by Las Vegas-based cannabis firm Planet 13 Holdings.

The membership interest purchase agreement will see Planet 13 Holdings acquire an operational greenhouse cultivation facility, an analytical and processing laboratory, and three product lines, including licensed brands Stanley Brothers, Tikun Olam and the VidaCann house brand. The state-of-the-art facility is fully operational and capable of supporting more than two times the volume of cannabis that flows through VidaCann’s and Planet 13’s dispensary networks combined.

According to Planet 13’s co-CEO Larry Scheffler, VidaCann is among the 10 largest marijuana operators in retail size in the entire state of Florida. Furthermore, Scheffler noted that the Florida-based cannabis company has developed a reputation for producing high-quality products and providing great customer service. Acquiring the company will allow Planet 13 to “significantly accelerate” its entry into the Florida market, Scheffler said, and also allow it to capture a greater share of the market.

Planet 13 currently has 13 retail operations in the state of California along with 4 leased retail operations in Florida; the company is also set to launch a retail store in Illinois.

Scheffler said that Planet 13 was partly drawn to the acquisition deal by the prospect of teaming up with VidaCann’s “amazing management team” as it has built VidaCann into the ninth largest marijuana company in the state with little outside capital and limited debt. Scheffler added that VidaCann’s management’s ability to run a lean and efficient operation would be a strategic and cultural fit to Planet 13’s philosophy of launching retail operations in other states.

The Las Vegas cannabis operator has outlined a set of goals to achieve after the acquisition deal is complete that will build VidaCann into an even stronger company next year, Scheffler concluded.

According to the purchase agreement, which received unanimous approval from both VidaCann managers and the Planet 13 Board of Directors, the acquisition deal should close in Q1 2024. Upon the deal’s closing, VidaCann will be granted the right to nominate a fifth member to Planet 13’s board of directors. As per the proposed agreement, former VidaCann shareholders will have a 26% pro forma ownership on a fully diluted basis in Planet 13 Holdings.

As these major players in the cannabis industry expand their footprint in different markets across the country, they inevitably create opportunities for other ecosystem actors such as Innovative Industrial Properties Inc. (NYSE: IIPR).

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Acquires High Times Intellectual Property, Featured in Financial News Media Article

Lucy Scientific Discovery (NASDAQ: LSDI) today announced the acquisition of the intellectual property (“IP”) of High Times, an iconic brand in the cannabis industry. In addition to the Hightimes.com domain, the transaction also includes the trademarks for the Cannabis Cup and 420.com brands and their respective domain names. In exchange, High Times will receive a 19.9% stake in Lucy’s outstanding stock as well as performance-based payments.

“Lucy expects this acquisition to drive high margin revenue quickly and sustainably across the cannabis sector around the world. This is a great opportunity to grow the market presence of the nearly 50-year-old High Times brand globally through licensing and online distribution,” Lucy Scientific Discovery Executive Chairman and CEO Richard Nanula stated in the news release. “We are confident that this opportunity can add significant value for our shareholders.”

In addition, Lucy Scientific Discovery (NASDAQ: LSDI) was featured in a Financial News Media article together with other companies active in the burgeoning global cannabis market, including SNDL Inc. (NASDAQ: SNDL), Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED), Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), and Tilray Brands, Inc. (NASDAQ: TLRY) (TSX: TLRY). The piece discusses opportunities in the market driven by increased legalization of cannabis and rising acceptance of its use for medical purposes. Statista projects that revenue in the global cannabis market is projected to reach US$51.27 billion in 2023, at an annual growth rate (“CAGR” 2023-2028) of 14.95%, resulting in a market volume of US$102.90 billion by 2028.

To view the full press release/article, visit https://cnw.fm/IdURM and https://cnw.fm/FjOGd

About Lucy Scientific Discovery Inc.

Lucy Scientific Discovery is a Nasdaq-listed company with holdings and operations in a variety of psychotropic businesses. The company holds a Controlled Drugs and Substances Dealer’s License granted by Health Canada’s Office of Controlled Substances. Lucy Scientific Discovery Inc. and its wholly-owned subsidiary, LSDI Manufacturing Inc., operate under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada). This specialized license authorizes LSDI to develop, sell, deliver, and manufacture pharmaceutical-grade active pharmaceutical ingredients (“APIs”) used in controlled substances and their raw material precursors. With a focus on pioneering innovative therapies for patients in need, Lucy Scientific Discovery Inc. is dedicated to advancing the understanding and applications of psychotropic medicines, improving mental health outcomes, and enhancing well-being for individuals worldwide. For more information, visit the company’s website at www.LucyScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to LSDI are available in the company’s newsroom at https://cnw.fm/LSDI

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Cannabis Shows Potential in Symptom Alleviation for Pediatric Cancer Patients

A recent study published in the “Cancer” Journal explores the potential advantages of utilizing cannabis for children undergoing cancer treatment, a group that contends with various symptoms resulting from the disease and its therapies. However, while promising, further exploration into appropriate dosing and safety is imperative.

Advances in diagnostics, surgery and radiation have elevated survival rates among pediatric cancer patients. Nevertheless, progress brings its own set of issues, including anorexia, pain, vomiting and nausea, which prove challenging to manage. Cannabis derivatives have emerged as a strategy to alleviate these symptoms in young cancer patients. However, its safety, effectiveness and dosing in this demographic remain largely uncharted.

The authors of the study note that “pediatric oncologists remain cautious about cannabis due to the dearth of substantiated evidence affirming its safety and efficacy within this context. There’s an urgency to comprehensively examine the current landscape of cannabinoid application in pediatric cancer, guiding the evolution of clinical trials scrutinizing the impact of diverse cannabis products on safety, dosing, and efficacy for this demographic.”

Researchers from the University of Manitoba undertook a systematic meta-analysis and review to evaluate the body of literature concerning the use of medicinal marijuana for alleviating symptoms in pediatric cancer cases. They drew upon resources such as the Cochrane Library, PsycINFO, Embase and MEDLINE.

A total of 34,611 citations were examined, involving various cannabis strains, quantities, forms, administration methods and indications, as well as clinical and demographic attributes. These citations also encompass documented efficacy outcomes and any resultant unfavorable incidents. From those, 19 studies along with 1,927 participants were considered suitable for the study.

Within these studies, diverse marijuana products emerged as potential solutions for tackling distinct symptoms. Primarily, cannabis demonstrated efficacy in countering chemotherapy-induced vomiting and nausea. The side effects linked to cannabis usage include dry mouth, drowsiness and vertigo. Importantly, none of the studies documented any severe adversities linked to cannabis use in alleviating cancer-related symptoms in pediatric patients.

Lead author Lauren E. Kelly, PhD, acknowledged the challenges in measuring overall advantages due to disparate outcomes and study designs. Kelly noted, “While interventions with active control groups showed the superiority of cannabinoids in countering nausea and vomiting, data scarcity persists concerning cannabinoids’ influence on sleep, mood, pain, and the holistic quality of life.”

The study’s limitations included the count of studies within the review, outcome reporting inconsistencies, and the absence of case-controlled or cohort studies in the analysis.

Kelly emphasized the pivotal importance of conducting more rigorous investigations into the effects of cannabinoids on pediatric cancer patients and sharing such findings with the healthcare sector, patients and parents, given the varying experiences reported by children in terms of benefits and adverse events.

As more information becomes available regarding the therapeutic potential of cannabis for specific groups or demographics of patients, marijuana companies such as SNDL Inc. (NASDAQ: SNDL) could tweak their products in order to avail the most suitable product to address the specific symptoms of those patients.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Emergency Rule Grants Missouri Foster Parents Permission to Grow Cannabis at Home

A newly filed emergency rule by the Missouri State Department of Social Services will now allow foster parents to possess and grow cannabis at home. The Department of Social Services issued the emergency rule on the basis that the existing policies preventing foster parents in the state from legally growing cannabis in their homes are in direct conflict with Missouri’s recreational cannabis law.

Recreational cannabis has been legal for adults aged 21 years and older since late 2022 when Missouri voters approved an adult-use cannabis measure. The legislation legalized the purchase and possession of up to three ounces of marijuana and allowed registered adults to grow up to six mature cannabis plants for personal use.

However, foster parents in Missouri have until recently been barred from exercising these cannabis-related rights. A statement attached to the emergency rule’s text noted that Rule 13 CSR 35-60.040, which currently prevents foster parents from possessing cannabis or cannabis-infused products, is in conflict with the state constitution, making it invalid. The changes made to the state rule outlining standards for foster care by the emergency rule will remain in effect until Feb. 23, 2024.

According to the emergency rule, foster parents must ensure their cannabis is inaccessible to their foster children, much like how they are required to store items such as alcohol, medication and matches. The rule also requires that foster parents grow their cannabis plants in a locked and enclosed facility to prevent access by foster children. However, foster parents still can’t consume marijuana in any way that produces vapor or smoke inside their homes.

Social services spokesperson Caitlin Whaley said in a public statement that the new rule is meant to keep foster children safe by protecting them from the dangers of secondhand smoke. She said that foster parents can smoke tobacco and cannabis outside their homes and away from the children, but they aren’t allowed to smoke in the foster children’s presence or while enclosed in a vehicle with foster children.

Interestingly, a study published in 2022 revealed that recreational cannabis legalization in Missouri may have resulted in a 10% reduction in foster-care admissions. Researchers behind the study posited that federal cannabis legalization could save hundreds of millions of dollars in the foster-care system annually.

Most if not all state cannabis programs have strict rules intended to keep children away from cannabis. These regulations include stringent packaging and marketing rules that prevent cannabis companies from packaging cannabis products or marketing them in a way that attracts children.

As the remaining hallmarks of prohibition are rolled back in states where marijuana has been legalized, a time may come when people and companies in Missouri will operate in an environment similar to what entities such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) enjoy in the jurisdictions where they have operations.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — DeSantis Reaffirms Opposition to Federal Cannabis Legalization

Ron DeSantis, the Florida governor and a contender for the 2024 presidential election on the Republican ticket, has restated his firm stance against the legalization of marijuana if he were to assume office. His argument asserts that the legalization of marijuana has contributed to the growth of the illegal market in Colorado — despite evidence to the contrary.

While engaging with supporters during a campaign event in Iowa over the weekend, a concerned attendee shared stories of individuals whose children had developed cannabis-induced psychosis. The individual queried DeSantis about his position on legalizing or rescheduling cannabis at the federal level should he ascend to the presidency. DeSantis responded, reiterating his unwavering stance against legalization, echoing viewpoints he had expressed in a similar vein back in June.

The conversation then shifted toward a broader discourse on the negative consequences of substance abuse. DeSantis highlighted the existence of an unregulated drug market in San Francisco, using it as an example to underscore his belief that prevailing policies have contributed to the deterioration of society by enabling drug use.

DeSantis acknowledged the existence of medical cannabis access in Florida through a voter-approved constitutional amendment. However, he emphasized that different states have handled cannabis regulation differently, and he expressed his disinclination to further increase its accessibility under his leadership.

The fate of cannabis legalization in Florida might not solely rely on DeSantis’s stance, as the state Supreme Court is currently deliberating on the inclusion of a marijuana legalization initiative on the 2024 ballot.

Although DeSantis didn’t substantiate his argument with data or references, various government and private analyses suggest that Colorado has witnessed a considerable reduction in illicit market influence since implementing legalization. Notably, a report by Whitney Economics and Leafly from the previous year indicated that the regulated industry accounts for 99% of adult-use cannabis sales in Colorado, signifying a successful transition from the illicit market.

Recent data from the city of Denver further bolstered the case for legalization. The report indicated a significant decrease in law enforcement’s handling of illegal marijuana in 2022, providing tangible evidence of legalization’s effectiveness in curbing illicit sales.

DeSantis’s opposition to marijuana legalization, despite a growing bipartisan trend in support of reform, is consistent with his historical stance. This standpoint is only one aspect of his multifaceted position on the matter, as he competes to maintain his position as the second-leading candidate in the Republican presidential nomination race.

On a policy level, DeSantis signed a bill that recently came into effect in Florida, imposing stricter regulations on medical marijuana advertising and manufacturing. The law prohibits any promotional content related to “recreational” marijuana use while also imposing more rigorous eligibility criteria for individuals working in the cannabis industry. Additionally, DeSantis signed a bill in June that prevents residents of sober living facilities from possessing or using medical marijuana, even if they possess a doctor’s certification for therapeutic use. This restriction does not extend to other doctor-prescribed medications.

In the same month, the governor enacted legislation prohibiting the sale of consumable hemp products, including cannabis-infused chewing gum, to individuals under the age of 21. This expanded the existing restriction on the purchase of smokable hemp by young individuals.

DeSantis’ opposition to federal cannabis legalization suggests that it may still take a while for politicians on Capitol Hill to enact federal drug policy reforms that align with the wishes of the people, just in the same way that the current U.S. president hasn’t pushed for major reforms as had been expected when he was elected. Countrywide cannabis legalization as enjoyed by companies such as Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) in Canada is still a dream for American enterprises.

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Survey Shows Patients Satisfied with Marijuana as Neuropathy Treatment

A recent survey has found that marijuana is equally effective in alleviating neuropathy symptoms as opioids, raising questions about the validity of previous studies that utilized government-grown cannabis with lower potency. The survey was conducted by NuggMD, a company that connects patients with medical marijuana recommendations, and it involved 603 participants who used marijuana primarily or secondarily for neuropathy.

In the study, neuropathy, a painful condition, was measured by patients who assessed their pain levels on a scale of 1 to 10 both prior to and after using marijuana as a remedy. The outcomes were promising, indicating considerable relief. The average pain score prior to using cannabis was 7.64, and it decreased to 3.44 after consumption, resulting in an average pain relief of 4.2 out of 10.

These findings were on par with or even better than conventional treatments such as prescription opioids, as demonstrated by previous research. For instance, a 2017 trial illustrated that acetaminophen and oxycodone, acetaminophen and ibuprofen, acetaminophen and codeine, and acetaminophen and hydrocodone provided pain relief scores of 4.4, 4.3, 3.9 and 3.5, respectively.

Only 10 states explicitly recognize neuropathy as a qualifying condition for medical cannabis.

The researchers also noted that although increasing cannabinoid dosages didn’t consistently lead to greater relief, patients generally benefitted from higher-potency marijuana containing over 20% THC. This observation might explain the discrepancy between NuggMD’s findings and previous studies that employed lower-THC marijuana.

Among the surveyed patients, the majority (58.6%) used cannabis flower with THC exceeding 20%. Fewer participants used concentrates (26.3%), sub-20% THC flower (11.1%), or noninhalable products (3.9%). In essence, patients who found cannabis effective predominantly chose high-potency products, which are widely available and notably more potent than research-grade government cannabis.

The study’s authors highlighted that the consistency lay in the use of high-potency marijuana with 20% or higher THC. They pointed out that much of the pain-relief research used cannabis products with less than 20% THC, leading to claims that THC isn’t effective for pain relief.

Until recently, federally sanctioned marijuana research solely utilized cannabis from a DEA-authorized farm, which was widely criticized for its quality. This research monopoly was disrupted when the DEA approved additional growers, offering a more diverse range of cannabis strains.

However, NuggMD’s findings imply that prior neuropathy studies might have been compromised due to low-THC products. Lawmakers have voiced concerns about researchers’ limited access to cannabis that resembles what’s actually available in dispensaries. Efforts to change this policy have advanced in Congress but have yet to pass. Despite President Joe Biden’s move to ease marijuana research last year, the final bill didn’t include provisions for scientists to acquire retail cannabis.

NIDA Director Nora Volkow also highlighted that this restriction, combined with cannabis’s Schedule I classification, has hindered comprehensive research into its benefits and risks.

The NuggMD study doesn’t establish causal evidence of cannabis’s efficacy in treating neuropathic pain but underscores patients’ preference for medical marijuana over alternative treatments. When asked about their choice if they lacked access to medical cannabis, most respondents were inclined to tolerate symptoms (128) or use alcohol (36) rather than opt for opioids (112).

This survey suggests that patients aren’t just buying medical cannabis products from enterprises such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) as part of a fad. The patients keep using those products because they experience relief from their symptoms.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

NECANN’s New York Cannabis & Hemp Convention Set to Empower the Cannabis Industry

Investors, business executives, researchers, and industry leaders, are invited to attend NECANN’s New York Cannabis & Hemp Convention to be held in Albany, New York from September 29 – 30, 2023. The highly anticipated event will focus on the latest trends in the cannabis and hemp industry. The convention serves as a unique platform to connect with industry leaders and explores the limitless possibilities within the cannabis and hemp sectors.

Featuring thought-provoking exhibits and engaging sessions, the New York Cannabis & Hemp Convention is designed to create a lasting impact on the participants. The immersive atmosphere will encourage attendees to share their experiences and gain valuable insights. As a perfect blend of opportunity, passion, and creativity, the two-day event will feature leading brands from different parts of the cannabis and hemp industries. Attendees will get an opportunity to explore a wide range of products.

Shaping the Cannabis and Hemp Industries

The main highlight of the convention is knowledge sharing. Keynote speakers and industry experts will take insightful seminars to discuss the latest trends and innovations in the industry. The thought-provoking panel discussions will provide a glimpse into the latest innovations in the industry. Attendees will get an opportunity to learn about industry trends, cannabis regulations, medical innovations, and investment opportunities.

The New York Cannabis & Hemp Convention will showcase the transformative potential of hemp across different industries, including food, textiles, construction, and beverages. It will enable participants to foster a collaborative environment that reveals innovative ideas and the latest advancements in the hemp industry. Attendees will get a golden opportunity to share their experiences, challenges, and stories, while ensuring an equitable cannabis landscape.

To learn more, please visit https://cnw.fm/CNM8x. 

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Judge Says NJ Police Officer Sacked for Marijuana Use Should Get Job Back

The cannabis-reform movement recently scored a win after a New Jersey administrative law judge ruled that another police officer who was fired for marijuana use must be reinstated. Administrative Law Judge Joann Lasala Candido ruled in favor of terminated police officer Omar Polanco last week.

Even though the Jersey City Police Department consented to New Jersey’s off-duty cannabis use policy that allowed even law enforcement to use cannabis during off-duty hours, the police department has fired multiple officers for testing positive for THC metabolites. However, the Civil Service Commission and two administrative law judges have now overruled the department’s decision in line with constitutional protections issued by New Jersey’s 2021 cannabis legalization law.

In addition to Candido’s ruling, earlier this month the state Civil Service Commission (CSC) and Administrative Law Judge Kimberly Moss ruled that the police department violated state law by firing officer Norhan Mansour for failing a THC test. Jersey City PD now has orders to reinstate both Mansour and Polanco with backpay, a major blow to both the city’s mayor and police chief.

Jersey City Mayor Steven Fulop has expressed opposition to the policy granting cannabis access to marijuana during off-duty hours and said that it would put law enforcement at risk of operating with impaired judgment.

In both Polanco’s and Mansour’s cases, Jersey City argued that federal laws banning “unlawful marijuana users” from possessing or buying firearms preempted the state’s cannabis laws. However, the judges specified that the rule did not apply to police as they could receive firearms after completing police academy training.

Like the two judges, the Civil Service Commission did not buy into the city’s argument, calling it “unpersuasive” and without the support of facts. The commission added that the department’s talking point about the federal ban on firearm purchases for marijuana consumers did not apply to police officers because they don’t have to fill out the federal form asking them to declare their cannabis use before they can obtain a firearm. Furthermore, the commission said that the police department’s actions were unjustified, reversed the termination and approved Norhan Mansour’s appeal.

Mansour’s lawyer Peter Paris likened Jersey City’s actions to firing a police officer for having a beer off-duty, only this case was much worse because New Jersey residents have the constitutional right to consume cannabis.

It is still unclear whether the three other Jersey City law enforcement officers who were terminated for positive THC tests and sued the city police department will have similar positive outcomes. However, these decisions by the courts in New Jersey to assert that police officers can consume marijuana while they aren’t on duty will likely allow members of the armed forces to indulge in state-legal marijuana. As this happens, demand for products sold by licensed entities such as Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) will grow.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.